Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LANTHEUS HOLDINGS, INC.

(LNTH)
  Report
Delayed Nasdaq  -  04:00 2022-12-07 pm EST
54.33 USD   -2.07%
12/06Lantheus Holdings Prices $500 Million Convertible Senior Notes Offering
MT
12/06Lantheus Holdings, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
12/06Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Sector news Diagnostic & Testing Substances
12/06Natera, Inc. Announces Publication of Clinical Experience Study with 18,984 Twin Pregna..
CI
11/30Transcript : Natera, Inc. Presents at Piper Sandler 34th Annual Healthcare Co..
CI
11/16Sector Update: Health Care Stocks Back Near Even
MT
11/16Sector Update: Health Care Stocks Narrowly Higher
MT
11/16BioMérieux and Jackson Family Wines Introduces Innovation for Wine Quality - BOTTLESAFE..
CI
11/16Natera Prices Common Stock Offering at $35 Per Share
MT
11/14Credit Suisse Adjusts Natera's Price Target to $55 From $70, Keeps Outperform Rating
MT
11/09Transcript : Natera, Inc. Presents at Credit Suisse 31st Annual Healthcare Co..
CI
11/08Natera Net Loss Narrows as Sales Jump in Q3, Ups Revenue Guidance; Shares Jump After-Ho..
MT
11/08Earnings Flash (NTRA) NATERA Posts Q3 Revenue $210.6M, vs. Street Est of $206.7M
MT
11/08Transcript : Natera, Inc., Q3 2022 Earnings Call, Nov 08, 2022
CI
11/08Natera, Inc. Revises Earnings Guidance for the Year 2022
CI
11/08Natera, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
CI
11/07Shenzhen New Industries Receives Provincial Registration Certificate for Parathyroid Ho..
MT
11/02Natera Awarded US Veterans Affairs Department Contract to Offer Minimal Residual Diseas..
MT
11/02Natera, Inc. Awarded National MRD Testing Contract by the U.S. Department of Veterans A..
CI
10/27DiaSorin dips over 9%, brokers cite cut to underlying sales growth outlook
RE
10/27Diasorin S.p.A. Revises Earnings Guidance for the Fiscal Year 2022
CI
10/27Transcript : DiaSorin S.p.A., Q3 2022 Earnings Call, Oct 27, 2022
CI
10/27Tranche Update on DiaSorin S.p.A.'s Equity Buyback Plan announced on May 30, 2022.
CI
10/27DiaSorin S.p.A. Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
CI
10/26Transcript : BioMérieux S.A., Q3 2022 Earnings Call, Oct 26, 2022
CI
10/25Autobio Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended Septem..
CI
10/20Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for t..
CI
10/11Tranche Update on Autobio Diagnostics Co., Ltd.'s Equity Buyback Plan announced on Marc..
CI
10/04Natera Says Study Data Shows Prospera Kidney Test's 'Superior' Potential in Forecasting..
MT
10/04Natera, Inc. Announces the Publication of the Latest Data from the Trifecta Study in Tr..
CI
09/30Insider Sell: Natera
MT
09/27Autobio Diagnostics Secure Nine Registration Certificates in China
MT
09/26BioMérieux Survey Finds Delay in Sepsis Diagnosis in Europe
MT
09/21BrightInsight and bioMérieux Announce Partnership to Launch Clinical Digital Solutions ..
CI
09/14Transcript : Natera, Inc. Presents at Baird 2022 Global Healthcare Conference..
CI
09/14Italy's DiaSorin Gets US FDA Nod For Simplexa COVID-19 Direct Testing Kit
MT
09/13Transcript : Natera, Inc. Presents at Morgan Stanley 20th Annual Global Healt..
CI
08/31Transcript : BioMérieux S.A., H1 2022 Earnings Call, Aug 31, 2022
CI
08/31BioMérieux S.A. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/31BioMérieux S.A. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/31Tranche Update on bioMérieux S.A.'s Equity Buyback Plan announced on May 24, 2022.
CI
08/25Credit Suisse Initiates Coverage of 20 Companies in Life Science Tools, Services, Diagn..
MT
08/25Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for t..
CI
08/22BioMérieux Wins US FDA's Breakthrough Device Tag for Antibiotic Susceptibility Test
MT
08/18Piper Sandler Raises Price Target on Natera to $70 From $60, Reiterates Overweight Rati..
MT
08/15Natera, Inc. Announces the Resignation of Monica Bertagnolli as Member of the Board and..
CI
08/11Natera Completes Enrollment for RenaCARE Study
MT
08/11Sector Update: Health Care Stocks Mixed Premarket Thursday
MT
08/11Natera, Inc. Announces Enrollment Completion for RenaCARE Study
CI
08/11Natera Files Pre-Submission With FDA for Prenatal Test
MT
08/10Natera, Inc. Announces Q-Sub Filing with FDA for its Panorama« NIPT
CI
08/10Transcript : Natera, Inc. Presents at Canaccord Genuity 42nd Annual Growth Co..
CI
08/10Autobio Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30,..
CI
08/09DiaSorin S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/05JPMorgan Adjusts Natera's Price Target to $100 from $80, Keeps Overweight Rating
MT
08/04Natera Q2 Net Loss Widens but Matches Street View; Revenue Rises Almost 40%, Topping An..
MT
08/04Transcript : Natera, Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04Earnings Flash (NTRA) NATERA Posts Q2 Revenue $198.2M
MT
08/04Natera Revised Revenue Guidance for the Full Year of 2022
CI
08/04Natera, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June ..
CI
08/03Transcript : DiaSorin S.p.A., H1 2022 Earnings Call, Aug 03, 2022
CI
08/03DiaSorin Boosts FY22 Guidance on Increased COVID-19 Test Sales
MT
08/03Tranche Update on DiaSorin S.p.A.'s Equity Buyback Plan announced on May 30, 2022.
CI
07/28France's BioMérieux Wins US FDA Nod for Kidney Stress Detection Test Nephrocheck
MT
07/18Natera Says Federal Circuit Court of Appeals Upholds Invalidation of CareDx Patents
MT
07/18Natera Secures Medicare Coverage for Muscle Invasive Bladder Cancer Test
MT
07/18Natera, Inc. Receives Written Confirmation from the CMS Molecular Diagnostics Services ..
CI
07/14Natera Selected for United healthcare's Preferred Laboratory Network
CI
07/06Evotec's Boehringer Ingelheim, bioMerieux Form Antimicrobials JV
MT
07/06Evotec, bioMérieux, Boehringer Form $41 Million JV Focused On Antimicrobial Resistance
MT
07/06Boehringer Ingelheim, Evotec and bioMérieux Launch Aurobac, Joint Venture to Fight Anti..
CI
07/02Tranche Update on Autobio Diagnostics Co., Ltd.'s Equity Buyback Plan announced on Marc..
CI
07/01Agnelli's Exor expands in healthcare with 10% stake in Institut Merieux
RE
07/01Agnelli's Exor to invest 833 million euros for 10% stake in France's Institut Merieux
RE
06/29Natera Says Study Validates Performance of Its Prospera Transplant Rejection Test
MT
06/20Autobio Diagnostics Co., Ltd.(XSSC:603658) dropped fr..
CI
06/17Shenzhen New Industries Biomedical Engineering Co., Ltd. Implements Final Cash Dividend..
CI
06/14Transcript : Natera, Inc. Presents at Goldman Sachs 43rd Annual Global Health..
CI
06/13Autobio Diagnostics Co., Ltd.(XSSC:603658) dropped fr..
CI
06/10Autobio Diagnostics Co., Ltd.(SHSE:603658) dropped fr..
CI
06/10Autobio Diagnostics Co., Ltd.(SHSE:603658) dropped fr..
CI
05/30DiaSorin S.p.A. announces an Equity Buyback for 1,500,000 shares, representing 2.68% of..
CI
05/24Natera, Inc. Announces Executive Changes
CI
05/24BioMérieux Receives Health Canada Approval for BIOFIRE« Blood Culture Identification 2 ..
CI
05/24BioMérieux S.A. commences an Equity Buyback Plan for 10% of its issued share capital, u..
CI
05/19BioMérieux Closes Purchase Of US-based Biotechnology Group Specific Diagnostics
MT
05/19BioMérieux S.A. completed the acquisition of remaining unknown shares in Specific Diagn..
CI
05/16Piper Sandler Adjusts Natera's Price Target to $60 From $75, Reiterates Overweight Rati..
MT
05/13Shenzhen New Industries Biomedical Engineering Co., Ltd. Approves Cash Dividend for 202..
CI
05/13BioMérieux Receives CE Marking For Automated Chikungunya Virus Tests
MT
05/09JPMorgan Adjusts Price Target for Natera to $80 From $150, Maintains Overweight Rating
MT
05/09Morgan Stanley Lowers Natera's Price Target to $70 From $110, Maintains Overweight Rati..
MT
05/06Transcript : DiaSorin S.p.A., Q1 2022 Earnings Call, May 06, 2022
CI
05/06DiaSorin S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05Natera's Q1 Loss Widens as Revenue Increases; Raises Full-Year 2022 Revenue Guidance
MT
05/05Transcript : Natera, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05Earnings Flash (NTRA) NATERA Posts Q1 Revenue $194.1M, vs. Street Est of $176.6M
MT
05/05Natera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05Natera, Inc. Revises Financial Guidance for the Year 2022
CI
05/04France's BioMérieux Wins US FDA Approval for Joint Infection Testing Panel
MT
04/29DiaSorin S.p.A.'s Equity Buyback announced on November 5, 2021, has expired.
CI
04/27Transcript : BioMérieux S.A., Q1 2022 Earnings Call, Apr 27, 2022
CI
04/26Natera Begins Study to Assess Clinical Use of Renasight in Diagnosis, Management of Chr..
MT
Upcoming event on LANTHEUS HOLDINGS, INC.